Bruker Daltonics Announces Launch of E2M Environmental & Emergency Mass Spectrometer for Real-Time On-Site GC/MS Chemical Analysis.GOTHENBURG, Sweden -- At the 9th International CBW cbw - Crypt Breakers Workbench Protection Symposium, Bruker Daltonics today announces the launch of its new Environmental & Emergency Mass Spectrometer, called the E(2)M[TM], a mobile, lightweight and rugged GC/MS GC/MS Gas Chromatograph/Mass Spectrometer GC/MS Gas Chromatograph/Mass Spectrometry GC/MS Gas Chromatograph/Mass Spectrograph system for fast, reliable onsite identification and quantification of organic substances in soil, air, water and on surfaces. The E(2)M instrument has been developed in close conjunction with fire brigades, first responders and disaster management authorities to provide the high specificity and analytical reliability of a gas chromatography mass spectrometer (GC/MS) in an easy-to-use, compact and fieldable instrument. Bruker Daltonics' robust E(2)M is the successor to the highly successful EM 640 and Viking GC/MS systems. The E(2)M is considerably lighter (35 kg) and smaller in size than its predecessors, while featuring further enhanced field analytical capabilities. It complements Bruker's military-hardened mil-spec MM-2 mobile mass spectrometers, used for CWA CWA Clean Water Act (33 USC) CWA Communications Workers of America CWA Concerned Women for America CWA CEN Workshop Agreement (European pre-normative document) CWA County Warning Area CWA Clean Water Action detection in defense applications. Training and operator skill requirements for the E2M have been significantly reduced and the reliability and robustness of this GC/MS system are impressive. The E(2)M can be mounted in vehicles or ships and can be operated while moving. It is designed to be used in a wide range of chemical detection applications, for example for infrastructure protection, for event security, for mobile emergency response, as well as for on-site analysis and environmental protection. The E(2)M is modular and offers several complementary sampling methods that fire brigades and other emergency services utilize during their missions. Mr. Sebastian Meyer-Plath, Bruker Daltonics' Vice President for Chemical, Biological, Nuclear and Radiation (CBRN CBRN Chemical, Biological, Radiological, and Nuclear CBRN Caribbean Basin Radar Network ) detection, commented: "Bruker Daltonics has more than two decades of experience with mobile mass spectrometers, and has worked with a large number of first responders and field analytical teams all over the world. Moreover, having worked alongside the German blue light services during the 2006 FIFA FIFA International Association Football Federation [French Fédération Internationale de Football Association] FIFA n abbr (= Fédération Internationale de Football Association) → FIFA f Football World Cup, several additional user requirements had to be taken into account. The result is our state-of-the-art E2M, designed to be the analytical backbone of first responders, blue light services and mobile analysis teams globally." Bruker Daltonics will exhibit at the 9th International Symposium on Protection against Chemical and Biological Warfare Agents in Gothenburg, Sweden, on May 22-25, 2007. ABOUT BRUKER BIOSCIENCES (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. , headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc., Bruker AXS Inc. and Bruker Optics Inc. For more information, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future, technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and, our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion